Eligible patients who have HF and were hospitalised/treated for an episode of worsening HF within the last 12 months. This non-randomised trial will enroll up to 15 patients and the primary safety and technical endpoints will be assessed at 3 months. Safety measures will include an assessment of all adverse events. Subjects will remain in this study for 24 months.
Early Feasibility Study of the FIRE1™ System in Heart Failure Patients to evaluate the feasibility and safety of implanting the FIRE1 system in stable HF patients